Proud Laureate of the PhD Paris Region Funding Initiative
June 21, 2019
Poster presentation on METAglut1™ our innovative IVD blood test at the meeting of SFNP 2022
February 2, 2022
January 15-17, 2020.
[EVENTS] Company ; METAglut1™
We are thrilled that our intermediate results of our validation study for METAglut1™ were shared for the first time at the 30st Congress of the Société Française de Neurologie Pédiatrique (SFNP), a key event dedicated to advancing the field of pediatric neurology in France.
This congress gathered leading experts, healthcare professionals, and researchers to discuss the latest developments, share knowledge, and collaborate on innovative approaches to n0uero-pediatric disorders.
We were particularly proud to have the intermediate results of our validation study for METAglut1™ presented by Dr. Domitille Gras, a neuropediatrician specialized in speech and cognitive disorders from the AP-HP Paris Region Hospitals (Assistance-Publique – Hôîtaux de Paris).
METAglut1™ is our first IVD blood test to aid the early diagnosis of Glut1 Deficiency Syndrom (Glut1DS), also known as De Vivo Disease, a rare metabolic disorder that can significantly impact the lives of affected children.
Sharing our intermediate results at the meeting of SFNP 2022 has invigorated our commitment to advancing research and innovation in pediatric health. We are dedicated to collaborating with experts and stakeholders to improve patient outcomes and have the test as fast as possible covered and available.
